Thera-SAbDab

MUROMONAB

>   Structural Summary
TherapeuticMuromonab
TargetCD3E
Heavy ChainQVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
Light ChainQIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQQWSSNPFTFGSGTKLEIN
100% seqID Fv Structure1sy6 [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2a
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)Discontinued
Recorded Developmental Technologyna
INN Year Proposed1988
INN Year Recommended1989
Companies InvolvedCancer Research UK, Ortho-McNeil, XOMA
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedDiabetes mellitus, Graft-versus-host disease, Renal transplant rejection, Rheumatoid arthritis
NotesLC IMGT 127 is N not K as in Jain paper.

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy